PT80426B - Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel - Google Patents

Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel

Info

Publication number
PT80426B
PT80426B PT80426A PT8042685A PT80426B PT 80426 B PT80426 B PT 80426B PT 80426 A PT80426 A PT 80426A PT 8042685 A PT8042685 A PT 8042685A PT 80426 B PT80426 B PT 80426B
Authority
PT
Portugal
Prior art keywords
pyridazinone
preparation
medicinal products
containing medicinal
alkoxy
Prior art date
Application number
PT80426A
Other languages
German (de)
English (en)
Portuguese (pt)
Other versions
PT80426A (de
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of PT80426A publication Critical patent/PT80426A/pt
Publication of PT80426B publication Critical patent/PT80426B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT80426A 1984-05-10 1985-05-09 Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel PT80426B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH229784 1984-05-10

Publications (2)

Publication Number Publication Date
PT80426A PT80426A (de) 1985-06-01
PT80426B true PT80426B (de) 1987-04-16

Family

ID=4230485

Family Applications (1)

Application Number Title Priority Date Filing Date
PT80426A PT80426B (de) 1984-05-10 1985-05-09 Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel

Country Status (15)

Country Link
US (1) US4665074A (enExample)
EP (1) EP0163965B1 (enExample)
JP (1) JPH062750B2 (enExample)
AT (1) ATE47844T1 (enExample)
AU (1) AU578947B2 (enExample)
CA (1) CA1245651A (enExample)
DE (1) DE3574137D1 (enExample)
DK (1) DK159431C (enExample)
ES (1) ES8607950A1 (enExample)
GR (1) GR851039B (enExample)
IE (1) IE58033B1 (enExample)
IL (1) IL75070A (enExample)
NZ (1) NZ211995A (enExample)
PT (1) PT80426B (enExample)
ZA (1) ZA853504B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59009351D1 (de) * 1989-04-17 1995-08-03 Byk Gulden Lomberg Chem Fab Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
EP0553174B1 (de) * 1990-10-16 1998-07-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Arylpyridazinone
WO1992019602A1 (de) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
EP0593567B1 (de) 1991-07-05 1996-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung substituierter pyridazine gegen dermatosen
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
ES2193539T3 (es) 1997-06-03 2003-11-01 Altana Pharma Ag Benzonaftiridinas.
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
EP1389468A4 (en) 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435244A1 (de) * 1974-07-22 1976-02-05 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
DE2445681A1 (de) * 1974-09-25 1976-04-15 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
JPS6037101B2 (ja) * 1977-03-09 1985-08-24 三共株式会社 フエニルピリダジノン誘導体の製法
DE2757923A1 (de) * 1977-12-24 1979-06-28 Hoechst Ag Verfahren zur herstellung von 3-pyridazonen
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
ES532337A0 (es) * 1983-05-11 1985-12-01 Byk Gulden Lomberg Chem Fab Procedimiento para la preparacion de 6-aril-3 (2h)piridazinonas
IT1173591B (it) * 1983-05-11 1987-06-24 Byk Gulden Lomberg Chem Fab Piridazioni,loro preparazione e impiego,farmaci contenenti piridazioni

Also Published As

Publication number Publication date
IL75070A0 (en) 1985-09-29
ZA853504B (en) 1985-12-24
GR851039B (enExample) 1985-05-28
IE851146L (en) 1985-11-10
EP0163965B1 (de) 1989-11-08
US4665074A (en) 1987-05-12
ATE47844T1 (de) 1989-11-15
DK177585D0 (da) 1985-04-19
NZ211995A (en) 1987-11-27
DK177585A (da) 1985-11-11
EP0163965A2 (de) 1985-12-11
EP0163965A3 (en) 1987-06-24
DK159431C (da) 1991-03-18
AU578947B2 (en) 1988-11-10
CA1245651A (en) 1988-11-29
ES542979A0 (es) 1986-06-16
DE3574137D1 (en) 1989-12-14
DK159431B (da) 1990-10-15
PT80426A (de) 1985-06-01
JPS60246375A (ja) 1985-12-06
JPH062750B2 (ja) 1994-01-12
IL75070A (en) 1988-11-15
ES8607950A1 (es) 1986-06-16
IE58033B1 (en) 1993-06-16
AU4177585A (en) 1985-11-14

Similar Documents

Publication Publication Date Title
PT80426A (de) Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel
ATE8384T1 (de) 1,1,2-triphenyl-but-1-en-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES8702371A1 (es) Un procedimiento para preparar nuevos derivados de 6-(4-fenilo sustituido -3(2h) piradazinona.
ATE34741T1 (de) 6-(acylaminoaryl)-3(2h)-pyridazinonderivate, ihre herstellung und verwendung.
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
PT78566A (de) Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel
NO301826B1 (no) Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler
PT82175A (de) Neue 3-pyridylmethylnaphthylderivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IE780279L (en) Imidazole derivatives
ES8604843A1 (es) Un metodo para la preparacion de un derivado de acetileno
IE791438L (en) Oxadiazolotriazines
AU573062B2 (en) Dihydrodithiazine derivatives
AU553493B2 (en) 3,7alpha-diazacyclohepta(j,k)fluoriene derivatives
NO932002L (no) Nye tiosemikarbazonsyreestere
MY102050A (en) Imidazole anologs of mevalonolactone and derivatives thereof
ATE3288T1 (de) 2-substituierte-6-phenyl-3(2h)-pyridazinonderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19951031